We conclude that SF3B1 overexpression represents a therapeutic vulnerability in PDAC that enables the targeting of splicing with Pladienolide-B not only in cancer cells but also in CSCs, which opens up novel therapeutic avenues for this lethal cancer. The gene discussed is SF3B1; the disease is cancer.